Table 4.
Serum LH and Te Concentrations in 40 Healthy Men after GnRH Administration
| Serum concentrations | Control | Ganirelix | Ketoconazole | ANOVA |
|---|---|---|---|---|
| Mean 2-h LH (IU/L) | 10.14 ± 1.09 | 6.94 ± 1.00 | 13.77 ± 1.52 | <0.0001* |
| Maximum LH (IU/L) | 14.65 ± 1.62 | 9.95 ± 1.54 | 19.24 ± 2.50 | <0.0001* |
| Amplitude LH (IU/L) | 10.5 ± 1.3 | 7.5 ± 1.4 | 12.8 ± 2.3 | <0.0001** |
| AUC LH (IU/L) | 1358 ± 146 | 913 ± 132 | 1834 ± 204 | <0.0001* |
| Testosterone | ||||
| Mean 2-h Te (ng/dL) | 392 ± 19 | 276 ± 21 | 61 ± 3.5 | <0.0001*** |
| Maximum Te (ng/dL) | 458 ± 21 | 368 ± 24 | 68 ± 4.6 | <0.0001*** |
| Amplitude Te (ng/dL) | 122 ± 7.1 | 178 ± 14 | 11 ± 2.7 | <0.0001*** |
| AUC Te (ng/dL*103) | 4.72 ± 0.23 | 3.32 ± 0.25 | 0.73 ± 0.04 | <0.0001*** |
Data are shown as mean and standard error of the mean. The General Linear Model was used for the ANOVA of Repeat Measurements. LH Contrasts were evaluated with the Bonferroni correction.
Abbreviations: AUC, area under the curve; LH, luteinizing hormone.
Serum concentrations: *Post-hoc contrasts: Control versus Ganirelix and Ketoconazole, P < 0.0001, Ganirelix vs Ketoconazole, P < 0.0001.**Ganirelix versus control and ketoconazole, P < 0.0001. Te analysis: Contrasts were corrected with the Bonferroni procedure. ***Control vs Ganirelix and Ketoconazole, P < 0.0001; Ganirelix vs Ketoconazole, P < 0.0001.